The Claim
In adults with heterozygous familial hypercholesterolemia (HeFH) who are already on statin therapy, administering 20 mg of oral enlicitide daily for 24 weeks results in a mean reduction of apolipoprotein B by 48.2%, compared to a 1.8% change with placebo, yielding a between-group difference of −49.1% (95% CI: −54.0% to −44.3%, p < 0.001), indicating a reduction in the number of atherogenic lipoprotein particles.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For adults with a genetic cholesterol problem who are already on cholesterol meds, taking a pill called enlicitide every day for 6 months might drastically lower a key heart disease risk protein in their blood.
See the scientific wording
In adults with heterozygous familial hypercholesterolemia (HeFH) on statin therapy, 20 mg daily oral enlicitide for 24 weeks reduces apolipoprotein B by a mean of 48.2% compared to a 1.8% change with placebo (between-group difference: −49.1%, 95% CI: −54.0% to −44.3%, p < 0.001), indicating reduction in the number of atherogenic lipoprotein particles.
What the research says
1 studyThe study tested the same pill, in the same people, for the same amount of time, and found exactly what the claim says: it greatly lowers a key blood protein linked to heart disease.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.